Avidity Biosciences 

Yahoo Finance • 2 months ago

Is Avidity Biosciences Inc. (RNA) the Best Performing Small-Cap Stock in 2024?

We recently compiled a list of the 10 Best Performing Small-Cap Stocks in 2024. In this article, we will look at where Avidity Biosciences Inc. (NASDAQ:RNA) ranks among the best-performing small-cap stocks in 2024. The Case for Small Caps... Full story

Yahoo Finance • 2 months ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Sept. 23, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that... Full story

Yahoo Finance • 3 months ago

Avidity Biosciences Announces Positive AOC 1044 Data Demonstrated Significant Increase of 25% in Dystrophin Production and Reduction of Creatine Kinase Levels to Near Normal in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in the Phase 1/2 EXPLORE44™ Trial

Delpacibart zotadirsen (AOC 1044) delivered unsurpassed muscle concentrations of PMO of 200 nM after three doses of 5 mg/kg Statistically significant 37% increase in exon 44 skipping and up to 66% skipping with delpacibart zotadirsen 5 mg... Full story

Yahoo Finance • 5 months ago

Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

SAN DIEGO, June 17, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that... Full story

Yahoo Finance • 7 months ago

Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1

Avidity initiating global Phase 3 HARBOR™ study for delpacibart etedesiran this quarter Delpacibart etedesiran data from MARINA-OLE™ showed reversal of disease progression in multiple functional measures in DM1 compared to END-DM1 natural... Full story

Yahoo Finance • 12 months ago

Avidity Stock Soars on Collaboration Deal With Bristol Myers

Bristol Myers has agreed to pay Avidity $60 million in cash and will also purchase about $40 million of Avidity common stock at $7.88 a share. Continue reading... Full story

Yahoo Finance • last year

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Avidity Biosciences, Inc. (NASDAQ: RNA) and Encourages Investors to Contact the Firm

PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Avidity Biosciences, Inc. (NASDAQ: RNA) (“Avidity”) on behalf of the company’s investors. Since February 2023, shares of Avidity’s common... Full story

Yahoo Finance • last year

Avidity Biosciences Reports Third Quarter 2023 Financial Results and Recent Highlights

Avidity reported new positive AOC 1001 data at World Muscle Society (WMS) Congress in October demonstrating consistent improvement in multiple additional functional endpoints and favorable long-term safety and tolerability in people living... Full story

Yahoo Finance • last year

Investor Alert: Abbott Cooper PLLC Announces Investigation into Avidity Biosciences, Inc.; Urges Avidity Stockholders to Contact Abbott Cooper Regarding Their Legal Rights

STAMFORD, Conn., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating Avidity Biosciences, Inc. (NASDAQ: RNA) (“Avidity” or the “Company”) on behalf of the Company’s investors to determine whether actions taken by Avidit... Full story

Yahoo Finance • 2 years ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avidity Biosciences, Inc. - RNA

NEW YORK, April 24, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Avidity Biosciences, Inc. (“Avidity” or the “Company”) (NASDAQ: RNA). Such investors are advised to contact Robert S. Willoughby... Full story

Yahoo Finance • 2 years ago

Investigation of Avidity Biosciences, Inc. (RNA) Announced by Holzer & Holzer, LLC

ATLANTA, April 20, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Avidity Biosciences, Inc. (“Avidity” or the “Company”) (NASDAQ: RNA) complied with federal securities laws. On March 30, 2023, Avidity provided an... Full story

Yahoo Finance • 2 years ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avidity Biosciences, Inc. - RNA

NEW YORK, April 09, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Avidity Biosciences, Inc. (“Avidity” or the “Company”) (NASDAQ: RNA). Such investors are advised to contact Robert S. Willoughby... Full story

Yahoo Finance • 2 years ago

Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock

SAN DIEGO, Dec. 15, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that... Full story